Oxgene Overview

  • Founded
  • 2011
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 94
Employees
  • Latest Deal Type
  • M&A

Oxgene General Information

Description

Developer biology-based technologies designed to aid in the discovery and development of biologics, cell, and gene therapies. The company's technologies specialize in DNA design, protein expression optimization, and cell line development technologies along with cloning platform and access to a library of matched plasmid inserts, enabling the bio-therapeutic industry to improve the overall efficiency through the application of synthetic biology.

Contact Information

Website
www.oxgene.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Parent Company
Primary Office
  • Medawar Centre
  • Robert Robinson Avenue
  • Oxford OX4 4GA
  • England, United Kingdom
+44 01865 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Oxgene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Merger/Acquisition 03-Mar-2021 000.00 Completed Generating Revenue
12. Later Stage VC 06-May-2020 00.000 000.00 Completed Generating Revenue
11. Later Stage VC 28-Mar-2019 00.000 000.00 000.00 Completed Generating Revenue
10. Later Stage VC 21-Aug-2017 000.00 000.00 000.00 Completed Generating Revenue
9. Grant 14-Feb-2017 00.000 00.000 Completed Generating Revenue
8. Early Stage VC 27-Oct-2016 00.000 00.000 00.000 Completed Generating Revenue
7. Early Stage VC 17-Mar-2016 00.000 00.000 00.000 Completed Generating Revenue
6. Early Stage VC 01-Dec-2015 00000 00.000 00.000 Completed Startup
5. Early Stage VC 09-Jun-2015 $232K $965K 00.000 Completed Startup
4. Early Stage VC 24-Dec-2014 $313K $733K 00.000 Completed Startup
To view Oxgene’s complete valuation and funding history, request access »

Oxgene Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Ordinary 00,000 00.000000 0000.0 0000.0 00 0000.0 00.000
C Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
C Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
B Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
B Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.000
A Ordinary 0,000 00.000000 000.00 000.00 00 000.00 0.00
A Ordinary 0,000 00.000000 000.0 000.0 00 000.0 0.000
A Ordinary 0,000 00.000000 000.00 000.00 00 000.00 0.000
A Ordinary 1,813 $0.013184 $58.17 $58.17 1x $58.17 1.9%
A Ordinary 3,400 $0.013184 $58.17 $58.17 1x $58.17 3.57%
To view Oxgene’s complete cap table history, request access »

Oxgene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer biology-based technologies designed to aid in the discovery and development of biologics, cell, and gene thera
Biotechnology
Oxford, United Kingdom
94 As of 2021
000.00
000000&0 000.00

0000000

minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Dui
0000000000000
London, United Kingdom
00 As of 0000
00.00 0000-00-00
000000&0

00000000

s nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
Alameda, CA
00 As of 0000
000000000 -
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oxgene Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bioline Reagents Formerly Accelerator/Incubator backed London, United Kingdom 00 000000&0
00000000 Corporation Alameda, CA 00 000000000 -
0000 000000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
000000000 00000000 Formerly VC-backed Billerica, MA 00 00000 000000&0 00000
0000000 000000000 Formerly VC-backed Tianjin, China 0000 00000 00000000000 00000
You’re viewing 5 of 26 competitors. Get the full list »

Oxgene Patents

Oxgene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-2592751-A Process for making adenoassociated viral vectors Pending 04-Feb-2020 0000000000 0
GB-2592752-A Dna amplification method Pending 04-Feb-2020 00000000 0
AU-2020235455-A1 Method of selecting for antibodies Pending 08-Mar-2019 00000000000
GB-2595404-A Inducible aav system comprising cumate operator sequences Pending 05-Feb-2019 000000000 0
JP-2021502799-A Retrovirus vector Pending 19-Sep-2017 C12N15/86
To view Oxgene’s complete patent history, request access »

Oxgene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oxgene Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Canaccord Genuity Investment Bank Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Invesco Asset Manager Minority 000 0000 000000 0
Invesco Perpetual Asset Manager Minority 000 0000 000000 0
Mercia Asset Management Venture Capital Minority 000 0000 000000 0
To view Oxgene’s complete investors history, request access »